STOCK TITAN

23andMe Holding Co - ME STOCK NEWS

Welcome to our dedicated news page for 23andMe Holding Co (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23andMe Holding Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 23andMe Holding Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 23andMe Holding Co's position in the market.

Rhea-AI Summary
23andMe reports Q1 FY2024 financial results, reaffirms full year revenue guidance, and raises full year guidance for net loss and adjusted EBITDA deficit. The company made progress in both its Therapeutics and Consumer businesses, with strong reception to the new price point of its 23andMe+ subscription service. Revenue for Q1 FY2024 was $61 million, a decrease of 6% compared to the same period last year. Operating expenses increased to $140 million, resulting in a net loss of $105 million. The company ended June 30, 2023, with cash and cash equivalents of $314 million. Full year revenue guidance for FY2024 is in the range of $255 million to $275 million, with a net loss projected to be in the range of $345 million to $325 million. Full year adjusted EBITDA deficit is projected to be in the range of $180 million to $160 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.93%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
none
23andMe Holding Co

Nasdaq:ME

ME Rankings

ME Stock Data

214.03M
312.08M
3.94%
43.11%
6.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About ME

23andme is the leading personal genetics company dedicated to helping individuals understand their own genetic information through dna analysis technologies and web-based interactive tools. the company's personal genome service® enables individuals to gain deeper insights into their ancestry and genetic make-up. the vision for 23andme is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andme was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science.